TuHURA Biosciences, Inc. (NASDAQ:HURA) Given Average Rating of "Buy" by Analysts

Key Points

• TuHURA Biosciences, Inc. (NASDAQ:HURA) has received an average recommendation of "Buy" from analysts, with three firms rating it as a buy and two as strong buy.
• The company's average 1-year price target is $12.67, despite recent stock prices hovering around $2.55.
• In its latest quarterly earnings report, TuHURA missed analysts' expectations with a reported loss of ($0.21) EPS versus the consensus of ($0.14).

Shares of TuHURA Biosciences, Inc. (NASDAQ:HURA - Get Free Report) have earned an average recommendation of "Buy" from the five research firms that are presently covering the stock, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. The average 1-year price objective among brokers that have covered the stock in the last year is $12.6667.

A number of analysts have weighed in on HURA shares. Brookline Capital Management upgraded TuHURA Biosciences to a "strong-buy" rating in a research note on Monday, June 23rd. HC Wainwright reiterated a "buy" rating and issued a $12.00 target price on shares of TuHURA Biosciences in a research note on Friday, May 16th. Finally, Wall Street Zen lowered TuHURA Biosciences from a "hold" rating to a "sell" rating in a research note on Saturday, August 30th.

TuHURA Biosciences Stock Performance

Shares of HURA opened at $2.55 on Friday. The business has a fifty day moving average of $2.67 and a 200 day moving average of $3.03. TuHURA Biosciences has a 52-week low of $1.80 and a 52-week high of $8.40.

TuHURA Biosciences (NASDAQ:HURA - Get Free Report) last issued its quarterly earnings results on Thursday, August 14th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.14) by ($0.07).

Institutional Trading of TuHURA Biosciences

A number of hedge funds and other institutional investors have recently bought and sold shares of HURA. Suncoast Equity Management increased its stake in shares of TuHURA Biosciences by 4.4% during the second quarter. Suncoast Equity Management now owns 104,409 shares of the company's stock valued at $233,000 after buying an additional 4,412 shares during the period. JPMorgan Chase & Co. purchased a new position in shares of TuHURA Biosciences during the second quarter valued at $27,000. Intech Investment Management LLC purchased a new position in shares of TuHURA Biosciences during the second quarter valued at $29,000. Jefferies Financial Group Inc. purchased a new position in shares of TuHURA Biosciences during the fourth quarter valued at $54,000. Finally, Invesco Ltd. purchased a new position in shares of TuHURA Biosciences during the second quarter valued at $30,000. Hedge funds and other institutional investors own 0.62% of the company's stock.

About TuHURA Biosciences

TuHURA Biosciences, Inc NASDAQ: HURA is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA's lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.